Affordable Access

Access to the full text

How COVID-19 is changing rheumatology clinical practice

Authors
  • Bonfá, Eloisa1
  • Gossec, Laure2, 3
  • Isenberg, David A.4
  • Li, Zhanguo5
  • Raychaudhuri, Soumya6, 7, 8
  • 1 Universidade de São Paulo, São Paulo, SP, Brazil , São Paulo (Brazil)
  • 2 Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France , Paris (France)
  • 3 AP-HP, Pitié Salpêtrière Hospital, Paris, France , Paris (France)
  • 4 University College London, London, UK , London (United Kingdom)
  • 5 Peking University People’s Hospital, Beijing, China , Beijing (China)
  • 6 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA , Boston (United States)
  • 7 Broad Institute of MIT and Harvard, Cambridge, MA, USA , Cambridge (United States)
  • 8 University of Manchester, Manchester, UK , Manchester (United Kingdom)
Type
Published Article
Journal
Nature Reviews Rheumatology
Publisher
Springer Nature
Publication Date
Nov 02, 2020
Volume
17
Issue
1
Pages
11–15
Identifiers
DOI: 10.1038/s41584-020-00527-5
Source
Springer Nature
License
Yellow

Abstract

Eloisa Bonfá is a full professor of rheumatology and the clinical director of the largest tertiary public hospital of Latin America. Her main clinical and research interests are systemic lupus erythematosus and autoimmunity, with relevant contributions in the fields of autoantibodies, vaccines and drug monitoring in autoimmune diseases. She graduated at the University of São Paulo Medical School, Brazil, and undertook specialist training in rheumatology in the same university followed by a 4-year rheumatology research fellowship at the Hospital for Special Surgery, New York. Laure Gossec is a professor of rheumatology at Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France. She has a half-time clinical position where she mainly sees patients with inflammatory arthritis, and a half-time teaching and research position. Her main research interests are patient-reported outcomes and quality of life, as well as e-health and big data in psoriatic arthritis, spondyloarthritis and rheumatoid arthritis and she has authored more than 350 papers. She is a past-chair of the epidemiology standing committee of EULAR. David Isenberg is the Academic Director of Rheumatology at University College London, UK. He has run both general and autoimmune rheumatic disease clinics for over 30 years. His major research interests are in the structure, function and origin of autoantibodies and improving the assessment of patients with autoimmune rheumatic diseases. Zhanguo Li is a professor and head of the department of rheumatology and immunology at the Peking University People’s Hospital, China. He is the past president of APLAR, and the president of the Clinical Immunology Committee at the Chinese Society for Immunology. He is Editor-in-Chief of the Chinese Journal of Rheumatology. His research interests are the mechanisms and immune therapy of rheumatic diseases, including rheumatoid arthritis and systemic lupus erythematosus. Soumya Raychaudhuri is a Professor at Harvard Medical School, and a practicing rheumatologist at the Brigham and Women’s Hospital Arthritis Center. He is also appointed at the Broad Institute, and the University of Manchester. He spends most of his time running a lab that is focused on defining mechanisms of disease in rheumatoid arthritis, and other immune-mediated diseases, using computational biology, genetics and functional genomics.

Report this publication

Statistics

Seen <100 times